Intensity Therapeutics, Inc. Common stock
INTSIntensity Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for solid tumors. The company aims to harness the body’s immune response to target and destroy cancer cells through its proprietary immunotherapy platforms. Based in the United States, Intensity Therapeutics is involved in research and development efforts to advance novel therapies for cancer patients.
Company News
Intensity Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference, where CEO Lewis H. Bender will discuss their lead investigational product INT230-6, a novel intratumoral cancer therapy designed to kill tumors and enhance immune system recognition.
Intensity Therapeutics has regained compliance with Nasdaq's minimum Stockholders' Equity Requirement after filing its Q2 2025 report, demonstrating sufficient cash to fund operations into the second half of 2026.
Intensity Therapeutics raised $11.3 million in capital, extended cash runway into late 2026, and continues clinical trials for INT230-6, an intratumoral cancer therapy showing promising early results in tumor reduction and immune system engagement.
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates. Amtech reported quarterly sales of $27.70 million, missing the analyst consensus estimate of $34.50 million. The company...
Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors. Nxu, shares rose 42.1% to $0.0278 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers XBP Europe Holdings, Inc. (NASDAQ: XBP) shares rose 150% to $14.20 in pre-...
